Phone: 503 418-9308
Fax: 503 418-9311
Center for Health and Healing
Mail code: CH13B
3303 SW Bond Avenue, Rm #13035
Portland, OR 97239
M.D. - 1979, Semmelweis Medical University, Budapest, Hungary
Internal Medicine (Board Cert.) - 1984, Postgraduate Med. Sch., Budapest, Hungary
Andras turned to full time basic biomedical research after seven years of clinical practice at a teaching hospital. He earned faculty appointment to The Scripps Research Institute (1987-1993, La Jolla), and then he worked in executive medical and scientific positions for small biotechnology companies (1994-1999, San Diego, Raleigh). He joined the BME department of Emory University Scool of Medicine (Atlanta) in 2000, and came to OHSU in 2004. His accomplishments include the first description of a rare disease (acquired protein C deficiency), 3 of 4 issued patents reduced to medical practice and one in development, 14 first-authored peer-reviewed publications, co-authorship on other papers and books chapters papers, numerous presentations, and direct contribution to the discovery and/or development of FDA-approved biomedical products and devices. He received research awards from the NIH, AHA, and other sources. He is elected member of the American Society of Hematology, as well as of several other professional organizations.
Current Research Goals
To determine the role of contact activation in acute intraluminal thrombus propagation using synthetic vascular grafts in a primate model of thrombosis and hemostasis. If the functionality of the contact system enzyme complex (FXI/FXII/KK/HMWK) is relevant to the pathogenesis of thrombosis, a FXI inhibitor could become the first safe antithrombotic agent.
To characterize the effects of endogenous protein C activation on acute arterial thrombogenesis and hemostasis using rationally engineered recombinant enzymes. A pharmacologically viable protein C activator could help utilize the body's own antithrombotic and antiinflammatory system similar to the way streptokinase and tPA became useful fibrinolysis activators.
- Gruber A, Hanson SR. Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood 102:953-5, 2003.
- Gruber A, Hanson SR. Potential new targets for antithrombotic therapy. Curr Pharm Des. 9:2367-74, 2003.
- Gruber A, Cantwell AM, Di Cera E, Hanson SR. The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J Biol Chem. 277:27581-4, 2002.
- Kim T, Murdande S, Gruber A, Kim S. Sustained-release morphine for epidural analgesia in rats. Anesthesiology 85:331-8, 1996.